134 related articles for article (PubMed ID: 17455342)
1. Sudden rise of crystal growth rate of nifedipine near T(g) without and with polyvinylpyrrolidone.
Ishida H; Wu T; Yu L
J Pharm Sci; 2007 May; 96(5):1131-8. PubMed ID: 17455342
[TBL] [Abstract][Full Text] [Related]
2. Crystallization rate of amorphous nifedipine analogues unrelated to the glass transition temperature.
Miyazaki T; Yoshioka S; Aso Y; Kawanishi T
Int J Pharm; 2007 May; 336(1):191-5. PubMed ID: 17184940
[TBL] [Abstract][Full Text] [Related]
3. Prediction of onset of crystallization in amorphous pharmaceutical systems: phenobarbital, nifedipine/PVP, and phenobarbital/PVP.
Caron V; Bhugra C; Pikal MJ
J Pharm Sci; 2010 Sep; 99(9):3887-900. PubMed ID: 20575050
[TBL] [Abstract][Full Text] [Related]
4. Molecular mobility-based estimation of the crystallization rates of amorphous nifedipine and phenobarbital in poly(vinylpyrrolidone) solid dispersions.
Aso Y; Yoshioka S; Kojima S
J Pharm Sci; 2004 Feb; 93(2):384-91. PubMed ID: 14705195
[TBL] [Abstract][Full Text] [Related]
5. Solid state and dissolution rate characterization of co-ground mixtures of nifedipine and hydrophilic carriers.
Friedrich H; Nada A; Bodmeier R
Drug Dev Ind Pharm; 2005 Sep; 31(8):719-28. PubMed ID: 16221606
[TBL] [Abstract][Full Text] [Related]
6. Crystallization of organic glasses: effects of polymer additives on bulk and surface crystal growth in amorphous nifedipine.
Cai T; Zhu L; Yu L
Pharm Res; 2011 Oct; 28(10):2458-66. PubMed ID: 21638137
[TBL] [Abstract][Full Text] [Related]
7. Preparation and transformation of true nifedipine polymorphs: investigated with differential scanning calorimetry and X-Ray diffraction pattern fitting methods.
Grooff D; Liebenberg W; De Villiers MM
J Pharm Sci; 2011 May; 100(5):1944-57. PubMed ID: 21259235
[TBL] [Abstract][Full Text] [Related]
8. Miscibility of nifedipine and hydrophilic polymers as measured by (1)H-NMR spin-lattice relaxation.
Aso Y; Yoshioka S; Miyazaki T; Kawanishi T; Tanaka K; Kitamura S; Takakura A; Hayashi T; Muranushi N
Chem Pharm Bull (Tokyo); 2007 Aug; 55(8):1227-31. PubMed ID: 17666850
[TBL] [Abstract][Full Text] [Related]
9. Solubility of small-molecule crystals in polymers: D-mannitol in PVP, indomethacin in PVP/VA, and nifedipine in PVP/VA.
Tao J; Sun Y; Zhang GG; Yu L
Pharm Res; 2009 Apr; 26(4):855-64. PubMed ID: 19052850
[TBL] [Abstract][Full Text] [Related]
10. Stabilization of low glass transition temperature indomethacin formulations: impact of polymer-type and its concentration.
Chokshi RJ; Shah NH; Sandhu HK; Malick AW; Zia H
J Pharm Sci; 2008 Jun; 97(6):2286-98. PubMed ID: 17879977
[TBL] [Abstract][Full Text] [Related]
11. A comparison of the physical stability of amorphous felodipine and nifedipine systems.
Marsac PJ; Konno H; Taylor LS
Pharm Res; 2006 Oct; 23(10):2306-16. PubMed ID: 16927182
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of crystallization behavior on the surface of nifedipine solid dispersion powder using inverse gas chromatography.
Miyanishi H; Nemoto T; Mizuno M; Mimura H; Kitamura S; Iwao Y; Noguchi S; Itai S
Pharm Res; 2013 Feb; 30(2):502-11. PubMed ID: 23104579
[TBL] [Abstract][Full Text] [Related]
13. A comparison of spray drying and milling in the production of amorphous dispersions of sulfathiazole/polyvinylpyrrolidone and sulfadimidine/polyvinylpyrrolidone.
Caron V; Tajber L; Corrigan OI; Healy AM
Mol Pharm; 2011 Apr; 8(2):532-42. PubMed ID: 21323367
[TBL] [Abstract][Full Text] [Related]
14. Solubilities of crystalline drugs in polymers: an improved analytical method and comparison of solubilities of indomethacin and nifedipine in PVP, PVP/VA, and PVAc.
Sun Y; Tao J; Zhang GG; Yu L
J Pharm Sci; 2010 Sep; 99(9):4023-31. PubMed ID: 20607809
[TBL] [Abstract][Full Text] [Related]
15. Investigating miscibility and molecular mobility of nifedipine-PVP amorphous solid dispersions using solid-state NMR spectroscopy.
Yuan X; Sperger D; Munson EJ
Mol Pharm; 2014 Jan; 11(1):329-37. PubMed ID: 24256090
[TBL] [Abstract][Full Text] [Related]
16. Increased dissolution and physical stability of micronized nifedipine particles encapsulated with a biocompatible polymer and surfactants in a wet ball milling process.
Li N; DeGennaro MD; Liebenberg W; Tiedt LR; Zahr AS; Pishko MV; de Villiers MM
Pharmazie; 2006 Jul; 61(7):595-603. PubMed ID: 16889066
[TBL] [Abstract][Full Text] [Related]
17. Phase behavior of poly(vinylpyrrolidone) containing amorphous solid dispersions in the presence of moisture.
Rumondor AC; Marsac PJ; Stanford LA; Taylor LS
Mol Pharm; 2009; 6(5):1492-505. PubMed ID: 19634917
[TBL] [Abstract][Full Text] [Related]
18. Studying the Impact of Modified Saccharides on the Molecular Dynamics and Crystallization Tendencies of Model API Nifedipine.
Kaminska E; Tarnacka M; Wlodarczyk P; Jurkiewicz K; Kolodziejczyk K; Dulski M; Haznar-Garbacz D; Hawelek L; Kaminski K; Wlodarczyk A; Paluch M
Mol Pharm; 2015 Aug; 12(8):3007-19. PubMed ID: 26101945
[TBL] [Abstract][Full Text] [Related]
19. Effects of spray drying process parameters on the solubility behavior and physical stability of solid dispersions prepared using a laboratory-scale spray dryer.
Kojima Y; Ohta T; Shiraki K; Takano R; Maeda H; Ogawa Y
Drug Dev Ind Pharm; 2013 Sep; 39(9):1484-93. PubMed ID: 22670826
[TBL] [Abstract][Full Text] [Related]
20. Differences in crystallization rate of nitrendipine enantiomers in amorphous solid dispersions with HPMC and HPMCP.
Miyazaki T; Aso Y; Yoshioka S; Kawanishi T
Int J Pharm; 2011 Apr; 407(1-2):111-8. PubMed ID: 21277962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
